The Russian Direct Investment Fund (RDIF) and the leading Indian pharmaceutical company Hetero have signed an agreement to produce more than 100 million doses per year of the Sputnik V coronavirus vaccine.
“RDIF and leading Indian drug manufacturer Hetero announce an agreement to produce more than 100 million doses per year in India of the world’s first ever registered Sputnik V coronavirus vaccine. The parties intend to start production of the vaccine in early 2021”, – the creators of the vaccine said on Twitter.
The Russian Sputnik V coronavirus vaccine was registered the first in the world. The drug was developed by the Center named after Gamalei. The effectiveness of the vaccine, confirmed by interim research results, was 95%.